Menu

Cancer Tissue Repository Launched

The Dana-Farber Cancer Institute will store tissue samples from patients with leukemia and lymphoma from which scientists can make patient-derived mouse models.

Apr 11, 2016
Jef Akst

WIKIMEDIA, RAMAOne method that is growing in popularity for testing drugs on specific cancer types is the creation of patient-derived xenografts (PDXs), in which researchers implant bits of cancerous tissue extracted from patients into mice for study. Today (April 11), the Dana-Farber Cancer Institute announced the launch of an open-source public repository of biopsy tissue collected from patients with leukemia and lymphoma. Researchers can register for the database, called the Public Repository of Xenografts (PRoXe), use its Web portal to search for PDX models of specific subtypes of blood cancers, and order frozen cells from which they can create xenograft mouse models.

“About 90 percent of compounds that show anti-cancer activity in pre-clinical tests don’t work when given to patients,” said Dana-Farber’s David Weinstock said in a press release. “By trying drugs in PDX models, we can ‘mimic’ large and expensive human clinical trials and get answers about efficacy more quickly, less expensively and without the need for patients to get investigational drugs that won’t work.” Weinstock and his colleagues published details of the new repository today (April 11) in Cancer Cell; a total of 95 different researchers from 14 institutions are listed as coauthors.

For now, PRoXe includes only blood cancers, which are easier to biopsy and successfully transplant than solid tumors. But Weinstock noted in the press release that he and his colleagues are now in talks with several universities to expand the repository to include other biopsy tissues.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.